Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Feature|Articles|September 24, 2026
What Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajar
Author(s)Dr. Remo Moomiaie-Qajar
Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.
Advertisement
Advertisement
The long, complex process that it takes to successfully bring a drug to market is one of the biggest issues mentioned by members of the pharmaceutical and biotech industries. From a business standpoint, investors are wary to spend money on a molecule only for it to take years to discover that it’s not a viable treatment.
Related to this article
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Advertisement
Advertisement